Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
- PMID: 23230431
- PMCID: PMC3515855
- DOI: 10.3389/fendo.2012.00158
Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
Abstract
Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are overexpressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtually all benign insulinomas highly overexpress GLP-1 receptors (GLP-1R). Targeting GLP-1R with the stable GLP-1 analogs (111)In-DOTA/DPTA-exendin-4 offers a new approach to successfully localize these small tumors. This non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. Malignant insulinomas, in contrast to their benign counterparts, express GLP-1R in only one-third of the cases, while they more often express the somatostatin type 2 receptors. Importantly, one of the two receptors appears to be always expressed in malignant insulinomas. The GLP-1R overexpression in selected cancers is worth to be kept in mind with regard to the increasing use of GLP-1 analogs for diabetes therapy. While the functional role of GLP-1R in neoplasia is not known yet, it may be safe to monitor patients undergoing GLP-1 therapy carefully.
Keywords: 111In-DOTA/DPTA-exendin-4; glucagon-like peptide-1; glucagon-like peptide-1 receptor; insulinoma.
Figures


References
-
- Baggio L. L., Drucker D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132 2131–2157 - PubMed
-
- Chatziioannou A., Kehagias D., Mourikis D., Antoniou A., Limouris G., Kaponis A., et al. (2001). Imaging and localization of pancreatic insulinomas. Clin. Imaging 25 275–283 - PubMed
-
- Christ E., Forrer F., Wild D., Clerici T., Braendle M., Maecke H., et al. (2012). Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients. Neuroendocrinology 96 24–24 - PubMed
-
- Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., et al. (2009). Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 94 4398–4405 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources